A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting

Background: Therapy resistance remains a serious dilemma in metastatic castration-resistant prostate cancer (mCRPC) with primary or secondary resistance frequently occurring against any given therapy. Available prognostic models for Abiraterone Acetate (AA) are specifically designed for either pre-...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Boegemann, Martin, Schlack, Katrin, Früchtenicht, Lena, Steinestel, Julie, Schrader, Andres Jan, Wennmann, Yvonne, Krabbe, Laura-Maria, Eminaga, Okyaz
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2019
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6707939/
https://ncbi.nlm.nih.gov/pubmed/31489117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27133
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы